Adela的联合创始人兼首席科学官丹尼尔·德卡瓦略博士荣获2025年加拿大盖尔德纳潜力奖，该奖项表彰在科学领域做出卓越研究贡献、并对人类健康持续产生影响的世界知名科学家-动脉网

Adela's Co-Founder & Chief Scientific Officer, Dr. Daniel De Carvalho, Receives 2025 Canada Gairdner Momentum Award Recognizing World-Renowned Scientists for Exceptional Scientific Research Contributions with Continued Potential for Impact on Human Health

CISION 等信源发布 2025-04-11 21:00



可切换为仅中文







The Canada Gairdner Awards celebrate the world's best biomedical and global health researchers

加拿大盖尔德纳奖表彰全球最优秀的生物医学和全球健康研究人员。

FOSTER CITY, Calif.

福斯特城，加利福尼亚州

，

April 11, 2025

2025年4月11日

/PRNewswire/ -- Adela, Inc. is proud to announce that

/PRNewswire/ -- Adela公司荣幸地宣布

Daniel De Carvalho

丹尼尔·德·卡瓦略

, PhD, Co-Founder and Chief Scientific Officer, has been honored with the prestigious Peter Gilgan Canada Gairdner Momentum Award recognizing his outstanding scientific contributions, including early breakthroughs in methylation and the discovery of Adela's best-in-class technology for blood-based cancer testing.

，博士，联合创始人兼首席科学官，荣获了享有盛誉的彼得·吉尔根加拿大盖尔德纳发展奖，以表彰他在甲基化领域的早期突破以及发现Adela用于基于血液的癌症检测的最佳技术等卓越科学贡献。

Dr. De Carvalho's contributions have the potential to transform cancer screening and surveillance by enabling earlier detection of many new and recurrent cancers with a blood test, resulting in more effective treatment..

德卡瓦略博士的贡献有可能通过血液检测实现对多种新发和复发性癌症的早期检测，从而转变癌症的筛查和监测方式，使得治疗更加有效。

继续阅读

Adela Co-Founder and Chief Scientific Officer, Daniel De Carvalho, PhD

Adela联合创始人兼首席科学官，丹尼尔·德卡瓦略博士

The Canada Gairdner Awards recognize outstanding researchers whose unique scientific contributions have increased the understanding of human biology and disease. Since 1957, 426 awards have been bestowed on laureates from over 40 countries, and of those awardees, 102 have gone on to receive Nobel Prizes..

加拿大盖尔德纳奖表彰那些其独特的科学贡献增加了对人类生物学和疾病理解的杰出研究人员。自1957年以来，已有426项奖项授予了来自40多个国家的获奖者，其中102名获奖者后来获得了诺贝尔奖。

The Gairdner Foundation is recognizing Dr. De Carvalho as a global leader in cancer epigenetics, immunotherapy, and liquid biopsy research for 'the ground-breaking discovery of the role of transposable elements in regulating anti-tumour immunity through viral mimicry, which holds transformative potential for cancer therapy, and for pioneering the development of a novel blood-based test for early cancer detection, classification, and therapy monitoring.'.

盖尔德纳基金会表彰德卡瓦略博士为癌症表观遗传学、免疫治疗和液体活检研究领域的全球领导者，因其“通过病毒模拟发现转座元件在调控抗肿瘤免疫中的作用这一突破性发现，这一发现对癌症治疗具有变革潜力，并且开创性地开发了一种基于血液的新型检测方法，用于癌症的早期检测、分类和治疗监测。”

The novel approach to blood-based cancer detection, discovered by Dr. De Carvalho at University Health Network's Princess Margaret Cancer Centre, overcomes a significant challenge in the field - isolating genomic material for sequencing. Dr. De Carvalho's approach specifically isolates the information-rich (methylated) regions of the genome through a high-affinity enrichment process, allowing efficient capture of extensive, biologically-relevant genomic information.

由大学健康网络的玛格丽特公主癌症中心的德卡瓦略博士发现的这种基于血液的癌症检测新方法，克服了该领域的一个重大挑战——分离用于测序的基因组物质。德卡瓦略博士的方法通过高亲和力富集过程，专门分离基因组中信息丰富的（甲基化）区域，从而有效捕获广泛且生物学相关的基因组信息。

This advancement allows a single platform to be applied across many use cases in cancer, and also enables greater opportunity to detect cancer signals in the blood compared to other technologies that target a smaller set of genomic regions. Adela is developing the technology for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED)..

这一进展使得一个平台可以应用于癌症的许多案例中，而且与针对较小一组基因组区域的其他技术相比，该平台还有助于更多地检测血液中的癌症信号。Adela 正在开发用于微小残留病灶 (MRD) 监测和多癌早期检测 (MCED) 的技术。

'We congratulate Daniel on this tremendous honor recognizing his profound contributions to the field of cancer research,' said

“我们祝贺丹尼尔获得这一崇高荣誉，以表彰他对癌症研究领域的深远贡献，”

Lisa Alderson

丽莎·奥尔德森

, CEO of Adela. 'Daniel's discoveries have the potential to improve the lives of the millions of people impacted by cancer each year. We are excited to take these breakthrough innovations forward with the development of Adela's genome-wide methylation platform to improve the diagnosis and management of cancer.'.

Adela首席执行官表示：“丹尼尔的发现有潜力改善每年受癌症影响的数百万人的生活。我们非常兴奋能够通过开发Adela的全基因组甲基化平台，将这些突破性创新向前推进，以改善癌症的诊断和管理。”

About Adela

关于阿德拉

Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability.

阿德拉正在开发一流的技术，通过用于微小残留病（MRD）监测和多癌早期检测（MCED）的血液测试来加速癌症诊断并改善其管理。阿德拉基于血液、无需组织的产品确保了癌症患者对MRD检测的普遍可及性，消除了对肿瘤组织可用性的依赖。

Adela's approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela's first product utilizing this genome-wide methylome enrichment platform was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in .

阿德拉的方法能有效捕获来自甲基化组的广泛且与生物学相关的基因组信息，相比那些针对较小范围基因组区域的平台，这种方法提供了更大的机会来检测血液中的癌症信号。阿德拉利用这一全基因组甲基化组富集平台的首款产品最近在临床上验证了其对头颈癌患者复发的预测和监测能力，并已发表。

Annals of Oncology

肿瘤学年鉴

. Adela's investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management and Labcorp. Find more information at

Adela的投资者包括F-Prime Capital、OrbiMed、Deerfield Management、Decheng Capital、RA Capital Management和Labcorp。更多信息请访问

adelabio.com

。

SOURCE Adela

来源阿德拉

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?